Tag
Low-dose rivaroxaban failed to reduce cardiovascular events but increased major bleeding in advanced CKD patients at high cardiovascular risk, underscoring the need for cautious anticoagulant use.
Elevated levels of inflammatory and cardiac biomarkers are linked to higher risks of venous thromboembolism and bleeding in cancer patients, according to a post hoc analysis of the AVERT trial.
A mediation analysis of the randomized ECLS‑SHOCK trial found that VA‑ECMO increased moderate–severe bleeding and vascular complications but these events did not statistically mediate 30‑day mortality in patients with acute myocardial infar
Comprehensive review of ARIES-HM3 trial findings showing aspirin avoidance with vitamin K antagonists in HeartMate 3 LVAD patients reduces bleeding without increasing thrombotic events, supported by analyses across subgroups and anticoagula
Continued oral anticoagulant therapy after ≥90 days for unprovoked VTE significantly lowers recurrence and mortality despite increased bleeding risk, offering a net clinical benefit consistent across anticoagulant types and treatment durati
A 3-center randomized pilot trial found that randomized allocation to low- versus moderate-intensity anticoagulation during venovenous ECMO is feasible, with lower major bleeding rates in the low-intensity arm and no clear excess of thrombo
Explore the causes, symptoms, and implications of ovulation bleeding, distinguishing between normal physiological occurrences and potential health concerns.
Early resumption of DOACs after serious bleeding in AF patients may lower stroke risk but significantly increases recurrent bleeding. Individualized decision-making and further research are recommended.
